The company said the investigational GIP, GLP-1 glucagon triple hormone receptor agonist may offer another option for both diabetes and obesity
This makes fat selection critical
Caitlyn Edwardsjoined more than 100 scientists, clinicians, executives, and investors at the sold-out UC Davis GLP-1 Discovery Forum in California
During concurrent use , patients should contact their healthcare provider if they experience: Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) Severe, persistent abdominal pain (often radiating to the back) with or without vomitingthis could indicate pancreatitis, a serious adverse effect associated with GLP-1 receptor agonists requiring urgent medical evaluation Unexplained fatigue, jaundice, or abdominal pain (potential liver concerns) Worsening gastrointestinal symptoms beyond typical semaglutide side effects New or unusual symptoms that may represent an adverse reaction Patients taking oral medications with a narrow therapeutic index should discuss timing and monitoring with their healthcare provider, as semaglutide's effect on gastric emptying may affect absorption
Licensed 503A pharmacy